Aveanna Healthcare (AVAH) Raises 2025 Revenue Guidance to $2.425B-$2.445B, Exceeding Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy AVAH?
Source: seekingalpha
- Revenue Guidance Increase: Aveanna Healthcare raised its 2025 revenue guidance to $2.425B-$2.445B, surpassing the previous estimate of $2.375B from November, indicating strong growth potential in the home healthcare sector.
- EBITDA Guidance Boost: The company increased its adjusted EBITDA forecast to nearly $318M-$322M, up from over $300M previously, reflecting improved operational efficiency and enhanced profitability.
- 2026 Outlook: Aveanna expects to generate $2.54B-$2.56B in revenue for 2026, slightly below the consensus of $2.57B, yet still indicating a sustained growth trajectory and competitive strength in the market.
- Investor Conference Preview: The financial guidance update coincides with the company's presentation at the J.P. Morgan Healthcare Conference in San Francisco, which is expected to attract investor interest and bolster market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVAH
Wall Street analysts forecast AVAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVAH is 10.33 USD with a low forecast of 9.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.700
Low
9.00
Averages
10.33
High
12.50
Current: 7.700
Low
9.00
Averages
10.33
High
12.50
About AVAH
Aveanna Healthcare Holdings Inc. is a provider of diversified home care platforms. Its segments include Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS segment includes private duty nursing (PDN) services, as well as pediatric therapy services. HHH segment includes home health services, as well as hospice and specialty program services. Its home health services involve the provision of in-home services to its patients by its clinicians, which include nurses, therapists, social workers and home health aides. Its hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Medical Solutions segment offers a line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. It also provides case management services to assist families and patients by coordinating the provision of services between insurers and other healthcare providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Health Care Stocks Rise, NYSE Health Care Index Shows Strong Performance
- Healthcare Stocks Rise: Late Wednesday afternoon, healthcare stocks broadly increased, reflecting growing market confidence in the healthcare sector, which may attract more investor attention to this field.
- NYSE Health Care Index Performance: The rise in the NYSE Health Care Index indicates a healthy overall condition for the industry, potentially driving up stock prices of related companies and enhancing investor returns.
- Market Trends: The positive performance of the healthcare sector may be linked to recent policy changes and increasing market demand, demonstrating sustained investor interest in healthcare services and products.
- Investor Confidence: The rise in healthcare stocks could bolster investor confidence in the broader market, especially amid increasing economic uncertainty, as the healthcare sector is viewed as a relatively safe investment choice.
See More
Aveanna Healthcare (AVAH) Raises 2025 Revenue Guidance to $2.425B-$2.445B, Exceeding Consensus
- Revenue Guidance Increase: Aveanna Healthcare raised its 2025 revenue guidance to $2.425B-$2.445B, surpassing the previous estimate of $2.375B from November, indicating strong growth potential in the home healthcare sector.
- EBITDA Guidance Boost: The company increased its adjusted EBITDA forecast to nearly $318M-$322M, up from over $300M previously, reflecting improved operational efficiency and enhanced profitability.
- 2026 Outlook: Aveanna expects to generate $2.54B-$2.56B in revenue for 2026, slightly below the consensus of $2.57B, yet still indicating a sustained growth trajectory and competitive strength in the market.
- Investor Conference Preview: The financial guidance update coincides with the company's presentation at the J.P. Morgan Healthcare Conference in San Francisco, which is expected to attract investor interest and bolster market confidence.
See More
Aveanna Healthcare Updates 2025 Guidance, Forecasts Revenue of $2.445 Billion
- 2025 Revenue Forecast: Aveanna Healthcare anticipates revenue for 2025 to reach approximately $2.445 billion, an increase from previous estimates, indicating sustained growth potential in the high-cost patient care sector.
- Net Income Outlook: The expected net income for 2025 is projected to be between $181 million and $220 million, reflecting the company's profitability and financial stability in the complex healthcare market.
- Initial 2026 Guidance: The company forecasts revenue for 2026 to be between $2.54 billion and $2.56 billion, demonstrating confidence in future growth despite not providing net income guidance due to market volatility.
- Adjusted EBITDA Expectations: The adjusted EBITDA for 2025 is expected to range from $318 million to $322 million, indicating ongoing efforts to enhance operational efficiency and cost control will continue to drive financial performance.
See More
Aveanna Healthcare's CCO Sells 36,015 Shares for $292,488 Amid Turnaround
- Insider Transaction: Aveanna Healthcare's Chief Compliance Officer sold 36,015 shares between December 30 and January 2 at a weighted average price of $8.12, totaling $292,488, marking the largest single open-market sale in the past year.
- Ownership Reduction: This transaction reduced Cunningham's direct holdings by approximately 11%, from 329,369 shares to 293,354 shares, highlighting the increased significance of each sale due to his diminished stake.
- Business Turnaround: Aveanna reported a 22.2% year-over-year revenue increase in Q3 to $621.9 million, with adjusted EBITDA soaring 67.5% to $80.1 million, prompting management to raise full-year revenue guidance to over $2.375 billion, indicating a significant business turnaround.
- Market Implications: While Cunningham's stock sale may attract attention, investors should focus on Aveanna's sustained margin expansion and cash generation, which are crucial for the company's future growth prospects.
See More
Aveanna Healthcare Executive Sells 36,015 Shares for $292,488
- Insider Selling: Patrick A. Cunningham, the Chief Compliance Officer of Aveanna Healthcare, sold 36,015 shares between December 30 and January 2 for a total of $292,488, representing 10.93% of his direct holdings, reducing his ownership to 293,354 shares, indicating a strategic adjustment in executive shareholding.
- Tax Obligation Impact: The sale was executed to satisfy tax obligations related to vested equity awards rather than discretionary selling, suggesting that executives remain optimistic about the company's long-term prospects.
- Performance Rebound: Aveanna Healthcare reported a 22.2% year-over-year revenue increase to $621.9 million in Q3, with adjusted EBITDA soaring 67.5% to $80.1 million, prompting management to raise full-year revenue guidance to over $2.375 billion, indicating a significant business turnaround.
- Strong Market Performance: Over the past year, Aveanna's stock has surged approximately 99%, significantly outperforming the S&P 500's 17% gain, reflecting strong market confidence in the company's ongoing operational improvements and future growth potential.
See More
Aveanna Healthcare (AVAH) Shares Drop to $7.68, RSI at 28 Indicates Oversold Condition
- Stock Decline: Aveanna Healthcare Holdings Inc (AVAH) shares fell to $7.68 on Friday, marking a 52-week low, indicating strong selling pressure that may undermine investor confidence in the stock.
- Oversold Signal: The current RSI reading of 28.0, significantly lower than the S&P 500 ETF's (SPY) 51.0, suggests that AVAH's stock may be oversold, prompting investors to look for buying opportunities to capitalize on a potential rebound.
- Historical Performance Comparison: With a 52-week low of $3.67 and a high of $10.32, the current trading price of $7.79 indicates that AVAH is within its volatility range, potentially attracting investors seeking to buy at a lower price point.
- Market Sentiment Analysis: While the current stock price is depressed, investors may view the RSI as a bottom-fishing signal; however, ongoing selling pressure could impact the company's ability to raise capital and its market image.
See More
Health Care Stocks Rise, NYSE Health Care Index Shows Strong Performance
- Healthcare Stocks Rise: Late Wednesday afternoon, healthcare stocks broadly increased, reflecting growing market confidence in the healthcare sector, which may attract more investor attention to this field.
- NYSE Health Care Index Performance: The rise in the NYSE Health Care Index indicates a healthy overall condition for the industry, potentially driving up stock prices of related companies and enhancing investor returns.
- Market Trends: The positive performance of the healthcare sector may be linked to recent policy changes and increasing market demand, demonstrating sustained investor interest in healthcare services and products.
- Investor Confidence: The rise in healthcare stocks could bolster investor confidence in the broader market, especially amid increasing economic uncertainty, as the healthcare sector is viewed as a relatively safe investment choice.
See More
Aveanna Healthcare (AVAH) Raises 2025 Revenue Guidance to $2.425B-$2.445B, Exceeding Consensus
- Revenue Guidance Increase: Aveanna Healthcare raised its 2025 revenue guidance to $2.425B-$2.445B, surpassing the previous estimate of $2.375B from November, indicating strong growth potential in the home healthcare sector.
- EBITDA Guidance Boost: The company increased its adjusted EBITDA forecast to nearly $318M-$322M, up from over $300M previously, reflecting improved operational efficiency and enhanced profitability.
- 2026 Outlook: Aveanna expects to generate $2.54B-$2.56B in revenue for 2026, slightly below the consensus of $2.57B, yet still indicating a sustained growth trajectory and competitive strength in the market.
- Investor Conference Preview: The financial guidance update coincides with the company's presentation at the J.P. Morgan Healthcare Conference in San Francisco, which is expected to attract investor interest and bolster market confidence.
See More
Aveanna Healthcare Updates 2025 Guidance, Forecasts Revenue of $2.445 Billion
- 2025 Revenue Forecast: Aveanna Healthcare anticipates revenue for 2025 to reach approximately $2.445 billion, an increase from previous estimates, indicating sustained growth potential in the high-cost patient care sector.
- Net Income Outlook: The expected net income for 2025 is projected to be between $181 million and $220 million, reflecting the company's profitability and financial stability in the complex healthcare market.
- Initial 2026 Guidance: The company forecasts revenue for 2026 to be between $2.54 billion and $2.56 billion, demonstrating confidence in future growth despite not providing net income guidance due to market volatility.
- Adjusted EBITDA Expectations: The adjusted EBITDA for 2025 is expected to range from $318 million to $322 million, indicating ongoing efforts to enhance operational efficiency and cost control will continue to drive financial performance.
See More
Aveanna Healthcare's CCO Sells 36,015 Shares for $292,488 Amid Turnaround
- Insider Transaction: Aveanna Healthcare's Chief Compliance Officer sold 36,015 shares between December 30 and January 2 at a weighted average price of $8.12, totaling $292,488, marking the largest single open-market sale in the past year.
- Ownership Reduction: This transaction reduced Cunningham's direct holdings by approximately 11%, from 329,369 shares to 293,354 shares, highlighting the increased significance of each sale due to his diminished stake.
- Business Turnaround: Aveanna reported a 22.2% year-over-year revenue increase in Q3 to $621.9 million, with adjusted EBITDA soaring 67.5% to $80.1 million, prompting management to raise full-year revenue guidance to over $2.375 billion, indicating a significant business turnaround.
- Market Implications: While Cunningham's stock sale may attract attention, investors should focus on Aveanna's sustained margin expansion and cash generation, which are crucial for the company's future growth prospects.
See More
Aveanna Healthcare Executive Sells 36,015 Shares for $292,488
- Insider Selling: Patrick A. Cunningham, the Chief Compliance Officer of Aveanna Healthcare, sold 36,015 shares between December 30 and January 2 for a total of $292,488, representing 10.93% of his direct holdings, reducing his ownership to 293,354 shares, indicating a strategic adjustment in executive shareholding.
- Tax Obligation Impact: The sale was executed to satisfy tax obligations related to vested equity awards rather than discretionary selling, suggesting that executives remain optimistic about the company's long-term prospects.
- Performance Rebound: Aveanna Healthcare reported a 22.2% year-over-year revenue increase to $621.9 million in Q3, with adjusted EBITDA soaring 67.5% to $80.1 million, prompting management to raise full-year revenue guidance to over $2.375 billion, indicating a significant business turnaround.
- Strong Market Performance: Over the past year, Aveanna's stock has surged approximately 99%, significantly outperforming the S&P 500's 17% gain, reflecting strong market confidence in the company's ongoing operational improvements and future growth potential.
See More
Aveanna Healthcare (AVAH) Shares Drop to $7.68, RSI at 28 Indicates Oversold Condition
- Stock Decline: Aveanna Healthcare Holdings Inc (AVAH) shares fell to $7.68 on Friday, marking a 52-week low, indicating strong selling pressure that may undermine investor confidence in the stock.
- Oversold Signal: The current RSI reading of 28.0, significantly lower than the S&P 500 ETF's (SPY) 51.0, suggests that AVAH's stock may be oversold, prompting investors to look for buying opportunities to capitalize on a potential rebound.
- Historical Performance Comparison: With a 52-week low of $3.67 and a high of $10.32, the current trading price of $7.79 indicates that AVAH is within its volatility range, potentially attracting investors seeking to buy at a lower price point.
- Market Sentiment Analysis: While the current stock price is depressed, investors may view the RSI as a bottom-fishing signal; however, ongoing selling pressure could impact the company's ability to raise capital and its market image.
See More
